Page 88 - JSOM Fall 2022

WWW.POLYSERPANTIVENOMS.COM BROAD-SPECTRUM, FREEZE-DRIED SNAKE ANTIVENOM / UNREFRIGERATED

PAN-AFRICA MENA

FOR USE IN AFRICOM AND CENTCOM

Antivenom administration in the field is the gold standard
of snakebite care and most e
ective way to reduce the risk
of death or permanent disability from snake envenomations.

Recommended by the Joint Trauma System
of the United States Defense Health Agency

Joint Trauma System Performance Improvement (PI) Monitoring FREEZE-DRIED / FIELD-STABLE SINGLE-SOURCE TREATMENT
“...Antivenom administration should be performed by medical providers capable of providing advanced life support and trained to a
minimum level of paramedic (or DoD equivalent) and higher (i.e. SOCM, 18D, PJ, IDC, IDMT, RN, PA, MD or DO, etc.)” Freeze-dried POLYSERP™ antivenoms are designed for use in austere POLYSERP™ antivenoms are effective against all 3 major snake
“...Early antivenom treatment is the standard of care for snake envenomations worldwide. Whenever possible, the appropriate environments and can be carried in the field unrefrigerated for 6 envenomation syndromes causing neurotoxic, hemotoxic, and cytotoxic
antivenom should be administered in the field prior to medevac to neutralize circulating venom before significant and potentially months at temperatures exceeding 100ºF without loss of potency. effects in a given region.
irreversible damage has occurred.”
“...Appropriate regional products listed in the CPG should be stocked in Role 2 and Role 3 medical facilities. Far-forward units with
paramedic level providers should be equipped with field-stable, broad-spectrum antivenoms that can be stocked in the aid station and ELIMINATE NEED FOR SNAKE IDENTIFICATION SAFE & EASY TO ADMINISTER IN THE FIELD
carried into the field for extended periods of times at high temperatures without loss of efficacy.”
Broad-spectrum POLYSERP™ antivenoms provide coverage against all POLYSERP™ antivenoms are the safest available in these regions, with
critical threat snake species in the regions they cover and enable a total incidence of early adverse reactions such as anaphylaxis of
medical providers to treat the patient based on the clinical syndrome just 0.2% in POLYSERP PAN-AFRICA and 1% in POLYSERP MENA.
of envenomation rather than the identity of the snake. Administer at the point of envenomation to prevent irreversible
damage to organ systems and local tissue before it has occurred.

Joint Trauma System Clinical Practice Guideline (JTS CPG). (2020, June 20).
Global Snake Envenomation Management: Guide providers in the evaluation
and treatment of patients after snake bites (CPG ID: 81). For more product information
https://jts.health.mil/assets/docs/cpgs/Global_Snake_Envenomation
_Management_30_Jun_2020_ID81.pdf WWW.POLYSERPANTIVENOMS.COM